Trust Signals
The tables separate administered animal amounts, human endogenous measurements, registered studies and calculation inputs. A registered study without results is not a published dose-response finding.Key Takeaways
- The current native-peptide study is NCT07505745, recruiting with no posted results.
- MOTS-c is a 16-amino-acid mitochondria-encoded peptide with a molecular weight of 2174.6 Da and sequence MRWQEMGYIFYPRKLR.
- A 10 mg vial reconstituted in 2 mL bacteriostatic water yields 5 mg/mL; a hypothetical 5 mg calculation input corresponds to 1 mL (100 U-100 volume units). This arithmetic does not select an amount to administer.
- WADA classifies MOTS-c as a prohibited peptide under S4.4.1 on the Prohibited List; competitive athletes face disqualification.
- No regulatory body has established a safe or effective clinical dose; all dosing information on this page is drawn from research or extrapolated from animal data and should not be taken as medical advice.
What is the standard MOTS-c dosage per day?
The reviewed sources do not establish a standard human amount per day. NCT07505745 describes a daily 12-week regimen, but the selected registry fields do not specify mg or provide results. CB4211 is a separate investigational analog, not an interchangeable source for native-MOTS-c dosing. The research chart below shows the amounts actually administered in named mouse experiments.
From the FormBlends catalog
MOTS-c
Mitochondrial-derived exercise mimetic that regulates metabolic homeostasis · From $249/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View MOTS-c →Table of Contents
- What is MOTS-c and why does the source peptide matter for dosing?
- Evidence ledger: what do we actually know?
- MOTS-c research chart by experiment, route and duration
- Mechanism and experiment amounts: what the mouse studies measured
- Operational guide: reconstituting a 10 mg vial
- What most pages get wrong about MOTS-c dosing
- Stability and formulation gotchas
- Honest head-to-head: MOTS-c vs. comparable interventions
- Label and COA literacy: how to judge a MOTS-c product
- MOTS-c dosage protocol: timing, cycle length, and stacking
- FAQ
- Sources
What is MOTS-c and why does the source peptide matter for dosing?
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded by the mitochondrial genome, not the nuclear genome. It was characterized by Lee et al. in a 2015 Cell Metabolism paper as an exercise-mimetic metabolic regulator. Its sequence is MRWQEMGYIFYPRKLR.
To get the units for your own vial, use the MOTS-c dosage calculator. Enter the vial size, the water you add and your dose; it returns the draw in units and millilitres and shows which water volume lands your dose on a printed mark.
The source matters for dosing because endogenous MOTS-c circulates in human plasma and changes with age and exercise. Younger adults have measurably higher circulating MOTS-c than older adults; exercise acutely raises levels. Exogenous dosing is therefore trying to supplement a signal that already exists, not introduce a foreign molecule. That said, exogenous doses in research protocols significantly exceed what physiological variation represents, so the pharmacological range being explored is well above normal physiology.
Evidence ledger: what do we actually know?
| Source | Actual experiment | Amount or result status | Interpretation |
|---|---|---|---|
| Lee et al., 2015 | Cells and mice | Named intraperitoneal mouse experiments | Animal metabolic outcomes |
| Reynolds et al., 2021 | Mouse treatment; human exercise measurements | No peptide administered in the ten-person human exercise arm | Human sampling is not a dose trial |
| NCT07505745 | Native MOTS-c versus placebo | Recruiting; 120 estimated; no posted results | Planned regimen, not established dose response |
| NCT03998514 | CB4211 Phase 1a/1b | Completed; 88 actual; no posted results | Different investigational analog |
MOTS-c research chart by experiment, route and duration
| Experiment | Amount as reported | Route and duration | Endpoint |
|---|---|---|---|
| Lee 2015, Figure 5 | 5 mg/kg/day | Mouse intraperitoneal, seven days | Glucose tolerance and insulin-sensitivity experiments |
| Lee 2015, Figure 6 | 0.5 mg/kg/day | Mouse intraperitoneal, eight weeks | High-fat-diet weight and metabolic outcomes |
| Reynolds 2021, young-mouse arm | 5 or 15 mg/kg/day | Mouse intraperitoneal, two weeks | Treadmill performance |
| Reynolds 2021, human exercise arm | None administered | Exercise with endogenous sampling | Muscle and circulating measurements |
| NCT07505745 | mg not supplied in selected fields | Registered subcutaneous daily regimen, 12 weeks | No posted results |
Sources: Lee original Figures 5-6, Reynolds original study and current native-MOTS-c registry. Multiplying a mouse mg/kg amount by a person's body weight would not supply a measured human exposure or recreate the experiment. The chart therefore preserves species and route instead of relabeling animal amounts as human equivalents.
Mechanism and experiment amounts: what the mouse studies measured
MOTS-c's primary mechanistic target is the folate cycle within the mitochondria. Lee et al. (2015) showed it inhibits the de novo purine biosynthesis pathway, which causes AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) to accumulate intracellularly. AICAR is an endogenous AMPK activator. The net result is AMPK activation, increased fatty acid oxidation, and improved glucose uptake in skeletal muscle.
Specific mechanistic data points from Lee et al. (2015):
- Lee 2015 Figure 5 used 5 mg/kg/day intraperitoneally for seven days in mouse insulin-sensitivity experiments; Figure 6 used 0.5 mg/kg/day for eight weeks in high-fat-diet mice.
- Lee 2015 reported AICAR accumulation and AMPK-related cellular findings; a cell-culture concentration is not a human vial amount.
- MOTS-c treatment reduced fat mass without altering total caloric intake in obese mice, implicating a metabolic reprogramming effect independent of appetite.
What this mechanism does NOT prove: In vitro AMPK activation at micromolar concentrations does not tell you what subcutaneous dose in a human achieves those local muscle concentrations. The tissue distribution and bioavailability of exogenous subcutaneous MOTS-c in humans is not established. The mechanism is plausible and well-characterized; the dose-response curve in humans is not.
10 mg MOTS-c vial math: concentration, volume and capacity
For a hypothetical 10 mg label quantity, concentration equals 10 mg divided by final volume. Volume for a selected calculation input equals that input divided by concentration. These are arithmetic inputs, not amounts established by the cited experiments.
| Final volume | Concentration | Calculation input | Corresponding volume | U-100 volume units | Capacity comparison |
|---|---|---|---|---|---|
| 1 mL | 10 mg/mL | 1 mg | 0.1 mL | 10 | Within 1 mL capacity |
| 1 mL | 10 mg/mL | 2.5 mg | 0.25 mL | 25 | Within 1 mL capacity |
| 1 mL | 10 mg/mL | 5 mg | 0.5 mL | 50 | Within 1 mL capacity |
| 1 mL | 10 mg/mL | 10 mg | 1 mL | 100 | Within 1 mL capacity |
| 2 mL | 5 mg/mL | 1 mg | 0.2 mL | 20 | Within 1 mL capacity |
| 2 mL | 5 mg/mL | 2.5 mg | 0.5 mL | 50 | Within 1 mL capacity |
| 2 mL | 5 mg/mL | 5 mg | 1 mL | 100 | Within 1 mL capacity |
| 2 mL | 5 mg/mL | 10 mg | 2 mL | 200 | Exceeds 1 mL capacity |
| 4 mL | 2.5 mg/mL | 1 mg | 0.4 mL | 40 | Within 1 mL capacity |
| 4 mL | 2.5 mg/mL | 2.5 mg | 1 mL | 100 | Within 1 mL capacity |
| 4 mL | 2.5 mg/mL | 5 mg | 2 mL | 200 | Exceeds 1 mL capacity |
| 4 mL | 2.5 mg/mL | 10 mg | 4 mL | 400 | Exceeds 1 mL capacity |
At 5 mg/mL, a 5 mg input corresponds to 1 mL, while a 10 mg input corresponds to 2 mL. The latter is a mathematical equivalent, not a drawable volume on a 1 mL syringe. U-100 describes 100 volume units per mL; it does not turn peptide mass into insulin activity units. BD capacity reference, page 39.
Reconstitution procedure: Use bacteriostatic water (0.9% benzyl alcohol), not plain sterile water, to extend usable life after reconstitution. Inject the water slowly down the inner wall of the vial, not directly onto the lyophilized cake. Swirl gently until dissolved. Do not vortex; mechanical shearing can degrade peptide tertiary structure. The solution should be clear and colorless.
Injection site: Subcutaneous injection into the abdomen or thigh, rotating sites. Clean with alcohol swab; allow to dry before injecting to avoid alcohol carry-in, which can irritate the peptide.
What most pages get wrong about MOTS-c dosing
1. A mass is not a study result. The 10 mg quantity in a vial-math example is a calculation input. The named experiments in the research chart do not establish it as a human daily amount.
2. Route must match the experiment. The cited mouse experiments used intraperitoneal treatment. The current native-peptide registry lists subcutaneous treatment. Neither supplies a measured human subcutaneous-versus-IV bioavailability comparison or establishes an exact absorbed fraction.
3. Human exercise sampling is not injected-peptide testing. Reynolds 2021 measured endogenous levels around cycling in ten men. That human arm cannot determine whether administering MOTS-c adds to, replaces or changes the response to training.
4. They omit WADA status. Any competitive athlete reading a dosage protocol that does not mention WADA S4.4.1 classification is receiving incomplete information.
Stability and formulation gotchas
Lyophilized powder: Store at -20 degrees Celsius before reconstitution. At room temperature, lyophilized peptides undergo slow hydrolysis and oxidation; methionine (M) and tryptophan (W) residues in MOTS-c's sequence are both oxidation-prone. Methionine oxidizes to methionine sulfoxide, and tryptophan can form kynurenine derivatives under oxidative or UV stress. Neither degradation product is the target molecule. This is why UV exposure and warm storage are disqualifying, not just suboptimal.
Why methionine matters specifically: The first residue in MOTS-c is methionine (M). Oxidation at the N-terminal methionine is a known degradation pathway for methionine-starting peptides and can alter receptor recognition. A COA confirming purity at manufacture does not guarantee purity at the time of injection if the vial has been stored improperly.
After reconstitution: Refrigerate at 2 to 8 degrees Celsius. Bacteriostatic water (0.9% benzyl alcohol) inhibits microbial growth but does not halt chemical degradation. The cited studies do not establish a 28-day period for this specific reconstituted formulation. When in doubt, use earlier rather than later.
Freeze-thaw cycles: Each freeze-thaw cycle causes mechanical stress to the peptide in solution from ice crystal formation. Aliquot before freezing if you will not use the full vial within 28 days. Freeze as small single-use volumes in low-protein-binding microtubes.
Honest head-to-head: MOTS-c vs. comparable interventions
| Intervention | Mechanism | Human RCT Evidence | Approval Status | Cost/Convenience | Where MOTS-c Loses |
|---|---|---|---|---|---|
| MOTS-c (exogenous) | AMPK activation via folate cycle / AICAR accumulation | Registered native-peptide study, no posted results | Not approved; research compound | High cost; injection required | No posted native-peptide results or measured oral-route comparison |
| Metformin | AMPK activation (partially overlapping); complex I inhibition | Extensive; thousands of patients across multiple RCTs | FDA-approved for type 2 diabetes | Very low cost; oral | MOTS-c loses badly on evidence depth and accessibility |
| Exercise (aerobic) | Raises endogenous MOTS-c; AMPK activation; mitochondrial biogenesis | Extensive RCT evidence for metabolic benefit | N/A | Zero cost; no injection | MOTS-c loses; exercise raises endogenous levels naturally |
| SS-31 (Elamipretide) | Mitochondrial inner membrane cardiolipin targeting; distinct from MOTS-c | Phase 2 data in heart failure; ongoing trials | Approved as Forzinity | High cost; injection | SS-31 has more advanced clinical trial data |
| AICAR (direct) | Direct AMPK activator (same downstream as MOTS-c) | Limited human data; used in some metabolic research | Not approved for general use | Research compound | MOTS-c: upstream signal; AICAR: direct but less physiological |
Label and COA literacy: how to judge a MOTS-c product
Minimum acceptable COA elements for injectable MOTS-c:
- HPLC purity: Greater than or equal to 98%. Values below 95% indicate significant impurity load. Impurities in an injectable research peptide are not benign.
- Mass spectrometry: The native sequence has a PubChem molecular weight of 2174.6 Da. Intact mass alone does not uniquely establish a sequence; identity and chromatographic purity are separate measurements.
- Sequence confirmation: MRWQEMGYIFYPRKLR. Ask for this explicitly if it is not on the COA.
- Endotoxin (LAL assay): A COA for an injectable peptide that does not include endotoxin testing is a disqualifying red flag. Lipopolysaccharide contamination causes fever and systemic inflammatory responses. The USP limit for injectable drugs is 0.5 EU/kg/hour; any reputable supplier should provide an endotoxin result.
- Moisture content: Lyophilized peptides with high residual moisture degrade faster. Karl Fischer titration should show moisture below about 6 to 8 percent.
Reading the label: Lot number and manufacture date should be present. If a vendor cannot provide a lot-specific COA (not a generic document), treat the product as unverified. Third-party testing from an independent laboratory carries more weight than internal certificates.
MOTS-c dosage protocol: timing, cycle length, and stacking
Timing: Community protocols most commonly administer MOTS-c in the morning, either fasted or pre-workout, based on the hypothesis that it amplifies exercise-induced metabolic signaling. There is no human pharmacodynamic data confirming that this timing window is optimal.
Cycle structure:
- Common protocol: 5 days on, 2 days off, for 4 to 12 weeks, followed by an equal-length break.
- Rationale for breaks: Precautionary; there is no evidence of receptor downregulation or tachyphylaxis from published data.
- There is no evidence-based duration; cycle structures are borrowed from general peptide-use convention.
Stacking: No human combination data exists. The most mechanistically distinct pairings seen in research-community use are MOTS-c with SS-31 (separate mitochondrial targets), or MOTS-c with BPC-157 (entirely different pathway). Stacking multiplies unknowns, not just benefits. A clinician should be involved before any combination protocol.
FAQ
What is the standard MOTS-c dosage per day?
The selected registry describes a daily 12-week study regimen without a posted mg amount or results. The original mouse chart preserves amount, species, route and duration. No regulatory body has approved a clinical dose.
What human MOTS-c dosing research is available?
NCT07505745 describes native MOTS-c with a fixed daily 12-week regimen, but its selected fields do not supply mg or results. NCT03998514 studied the separate CB4211 analog and has no posted results.
How do I reconstitute a 10 mg MOTS-c vial?
Add 2 mL of bacteriostatic water to a 10 mg vial to yield a concentration of 5 mg/mL (5,000 mcg/mL). For a 5 mg dose, draw 1 mL (100 units on a U-100 syringe). For a 10 mg dose, draw 2 mL. Swirl gently; never vortex. Use within 28 days refrigerated.
Is subcutaneous or intravenous MOTS-c better?
The selected sources do not compare these routes in humans. An intraperitoneal mouse experiment, a registered subcutaneous regimen and a human endogenous measurement answer different questions.
What is the MOTS-c half-life and how does it affect dosing frequency?
The selected sources do not provide a human plasma half-life sufficient to derive an optimal dosing frequency. A daily registry regimen is a study design, not a half-life calculation.
How long should a MOTS-c cycle last?
No human trial data defines an optimal cycle length. Community protocols typically run 4 to 12 weeks with breaks of equal length. There is no evidence-based rationale for a specific cycle duration; the break periods are precautionary, not pharmacologically justified by published research.
What are the known side effects at typical self-experimentation doses?
The two cited registries have no posted results, so event frequencies cannot be calculated from them. The reviewed cell and mouse experiments do not measure adverse-event rates for human 5-10 mg subcutaneous use.
Does MOTS-c need to be cycled with exercise for efficacy?
The cited human exercise arm measured endogenous MOTS-c and did not administer it. The mouse treatment and human sampling arms cannot be combined into a human exercise-dosing comparison.
How do I verify the purity of a MOTS-c peptide before use?
Request a Certificate of Analysis (COA) showing HPLC purity above 98% and mass spectrometry confirmation of the correct molecular weight (2174.6 Da for the 16-mer). Confirm the correct sequence: MRWQEMGYIFYPRKLR. Absence of endotoxin testing (LAL assay) on a COA for injectable peptide is a disqualifying red flag.
Can MOTS-c be stacked with other peptides?
No human combination trial data exists. Community protocols combine MOTS-c with BPC-157 or SS-31 (another mitochondrial peptide). The mechanistic rationale is plausible given different targets, but additive safety risks and pharmacokinetic interactions are entirely unstudied.
Is MOTS-c banned in sport?
MOTS-c is listed on the WADA Prohibited List under the Hormone and Metabolic Modulators category (S4.4.1) as a peptide with the potential to enhance performance by modulating metabolism. Athletes subject to anti-doping rules should treat it as prohibited.
What does a degraded MOTS-c vial look like?
A degraded vial may appear visibly cloudy, develop visible particulates, or have a yellowish tint instead of a clear, colorless solution. Any of these features means the vial should be discarded. Degradation can also be invisible; never use a vial stored improperly even if it appears clear.
Sources
- Lee et al., 2015, original full text, PMID 25738459.
- Reynolds et al., 2021, PMID 33473109.
- Kim et al., 2018, nuclear translocation, PMID 29983246.
- NCT07505745, native MOTS-c registry.
- NCT03998514, CB4211 registry.
- PubChem CID 146675088, molecular identity.
- WADA 2026, page 11.
- FDA Forzinity trial snapshot.
Disclaimers
Platform: FormBlends is an informational platform. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a licensed physician before using any research compound or peptide.
Research Compound: MOTS-c is not approved by the FDA or any regulatory agency for therapeutic use in humans. It is available as a research compound only. Use outside of an approved clinical trial is not regulated and carries unknown risks.
Results: Individual results referenced in animal or early human studies may not be representative of outcomes in the general population. Metabolic responses vary by individual health status, age, body composition, and concurrent medications.
Trademark: MOTS-c is a term associated with research originally conducted and published by the laboratory of Changhan David Lee at the University of Southern California. All product names, trademarks, and registered trademarks are the property of their respective owners. FormBlends has no affiliation with any peptide manufacturer referenced or implied on this page.
Related peptide guides
Ready when you are
MOTS-c
Mitochondrial-derived exercise mimetic that regulates metabolic homeostasis · From $249/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View MOTS-c →